Jeffrey W. Moses

Jun 13, 2024 | jamanetwork.com | Robert W. Yeh |Ajay Kirtane |Richard A Shlofmitz |Jeffrey W. Moses

Coronary In-Stent Restenosis Treated With Paclitaxel-Coated Balloon vs Uncoated Balloon—Reply Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis Robert W. Yeh, MD, MSc; Richard Shlofmitz, MD; Jeffrey Moses, MD; William Bachinsky, MD; Suhail Dohad, MD; Steven Rudick, MD; Robert Stoler, MD; Brian K. Jefferson, MD; William Nicholson, MD; John Altman, MD; Cinthia Bateman, MD; Amar Krishnaswamy, MD; J. Aaron Grantham, MD; Frank J.

Mar 9, 2024 | jamanetwork.com | Robert W. Yeh |Richard A Shlofmitz |Jeffrey W. Moses |William Bachinsky

Key PointsQuestion  Is treatment with a coronary paclitaxel-coated balloon superior to an uncoated balloon for 1-year target lesion failure in patients undergoing percutaneous coronary intervention for in-stent restenosis? Findings  In a multicenter randomized trial of 600 patients designed to support US regulatory approval, target lesion failure was significantly lower in the paclitaxel-coated balloon group (17.9%) compared with the uncoated balloon group (28.6%) (P = .003).